Nanobiotix SA

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

05 مايو 2025 02:00:00 بحسب Nasdaq GlobeNewswire

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

30 أبريل 2025 02:00:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

14 أبريل 2025 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

02 أبريل 2025 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

31 مارس 2025 02:00:00 بحسب Nasdaq GlobeNewswire

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

27 مارس 2025 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

20 مارس 2025 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

17 مارس 2025 16:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 مارس 2025 17:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

12 فبراير 2025 16:15:00 بحسب Nasdaq GlobeNewswire

Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025

29 يناير 2025 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

21 يناير 2025 02:30:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

09 يناير 2025 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024

17 ديسمبر 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 ديسمبر 2024 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

09 ديسمبر 2024 16:15:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

13 نوفمبر 2024 16:15:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

12 نوفمبر 2024 02:30:00 بحسب Nasdaq GlobeNewswire

NANOBIOTIX to Participate in Multiple Investor Conferences in November

31 أكتوبر 2024 03:30:00 بحسب Nasdaq GlobeNewswire

Voting Rights and Shares Capital of the Company

11 أكتوبر 2024 16:15:00 بحسب Nasdaq GlobeNewswire